|
|
Agenda
This special one-day Summit is held in conjunction with Beijing’s premier life science conference, the Beijing International Annual Healthcare Industry Forum. The BioCapital China Summit will explore the state of China’s rapidly growing biotech industry and the financial drivers that will determine its success. The SEED Business Plan Competition will also be introduced.
|
09:00-09:05
|
Opening of the Summit
|
|
09:05-09:20
|
Welcome Remarks by:
Zegong Zhang - Deputy Director, Beijing Pharma and Biotech Center
Zhen Wen - Director, Administration Committee,Daxing Bio-Medicine Industry Park, Zhongguancun Science Park
Limin Yuan - Director, Investment Promotion Bureau of Changping, Beijing
|
|
09:20-09:40
|
Keynote Speech: The State of China Biotech
China's rapidly growing life science industry is moving quickly from services to innovation. Hear the latest update on novel technology development, investment, IPO, M&A and partnering deals, and other data developed by ChinaBio's research team.
Greg B. Scott -Founder and CEO, ChinaBio® LLC
|
|
Section I: The Current Investment Opportunity – Biotech Industry Strong and Growing
|
|
09:40-10:40
|
Panel: The Evolving Investment Climate - Issues and Opportunities
While the financial crisis has impacted the world economy, China's biotech industry has been mostly spared, and is, in fact, showing strong signs of growth. This panel looks at the current investment climate for China biotech, including the opportunities presented by China's unique situation, and issues facing the industry and companies in overcoming the current slowdown in investment.
Moderator: Rajesh Parekh, PhD - Director, Head of Asia Healthcare Practice, McKinsey & Company
Panelists:
Carl Firth, PhD, MBA - Director, Head of Asia Healthcare, Bank of America Merrill Lynch
Shen Jun - General Manger, Beijing Junweicheng Credit Ratings Co., Ltd.
Erick Rabins - Senior Vice President of Strategic Affairs, Chief Business Development Officer, C3 Jian, Inc.
Yanning Yi, MBA - Vice President, The Balloch Group
|
|
10:40-10:55
|
Tea Break
|
|
Section II: Industry Leading Fund – Accelerating China’s Biotech Industry
|
|
10:55-11:15
|
Topic: How Government Funds Can Help Biotech Companies Grow
China's venture funding environment is rapidly changing in this time of economic turmoil, with government taking an ever more prominent role. This panel explores funding sources available to early stage life science companies in China
Jianjun Liu - Researcher/Former Deputy Director, Venture Capital Research Center of Peking University
|
|
11:15-12:15
|
Panel: How to Attract Funding - What VCs Really Want
Venture capitalists are the life blood of life science companies, which require significant capital to reach the market. Positioning a company to secure VC funding can be a challenge, especially in these times when capital is tight. Hear from VCs exactly what they look for, and how a company can attract their attention and money.
Moderator: Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia
Panelists:
Yi Lin, PhD, MBA - Executive Director, Mingly China Growth Fund
Yi Shi, PhD - Managing Director, Lilly Asian Ventures
Sherry Yin, LLM - Partner, Morrison & Foerster LLP
Weiren Zhu - Partner, Acorn Fund
|
|
12:15-13:30
|
Lunch
|
|
Section III: “Scientists to Entrepreneurs, Education and Development” – SEED Competition
|
|
13:30-13:40
|
Topic: Introduction to the SEED Business Plan Competition
SEED – Scientists to Entrepreneurs, Education and Development, is a life sciences and healthcare business plan competition created to develop and foster a community of scientists, healthcare professionals and entrepreneurs and create a platform for commercialization of life sciences and healthcare innovation in China. Created by a group of leading global pharmaceutical and biotech companies, venture capitalists, and business consultants, SEED will provide aspiring entrepreneurs with coaching and feedback from the leading players in China’s investment community and healthcare industry. The top prize will be over RMB 300,000. For more info, visit www.SEEDCompetition.com.
Stella Xu, PhD - Global Licensing Executive Director, Roche Global Pharma Partnering
|
|
13:40-14:20
|
Topic: From Research to Commercialization
Starting a company can appear to be a daunting challenge to most scientists, but the personal and financial rewards can be tremendous. SEED can help scientists take this first big step by providing a platform for emerging entrepreneurs on how to move their business concept from idea to reality. Specific examples of successful biotech companies will be given illustrating how technology can move from the lab to the market.
Joseph McCracken, DVM - Head of Pharma Partnering Asia, Roche Pharma Partnering
Rajesh Parekh, PhD - Director, Head of Asia Healthcare Practice, McKinsey & Company
|
|
14:20-14:40
|
Topic: Success Story – Beijing Company Makes Good
Dr. Wu co-founded CrownBio in 2006, and has taken it from a concept through funding to market. Based in Beijing's premier life science park, Zhongguancun, CrownBio is a member of ABO, a service company trade organization.
Alex Wu, PhD - CEO, Crown Bioscience, Inc.
|
|
14:40-15:40
|
Panel: Building a Global IP Portfolio
To compete effectively on the world market, China life science companies must establish a strong IP portfolio that stands up to global standards. This panel examines what it takes to build a global IP portfolio that will attract funding and fend off competitors.
Moderator: Catherine Sun, LLM - Managing Partner, Foley & Lardner LLP
Panelists：
Frank Grams, PhD - Executive Director, Roche Global Pharma Partnering
Esther H. Lim, JD - Founding Managing Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai Office
Rajesh Parekh, PhD - Director, Head of Asia Healthcare Practice, McKinsey & Company
Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed Asia
|
|
15:40-15:55
|
Tea Break
|
|
Section IV: Listing of China Biotech on Public Markets – Financing Opportunities
|
|
15:55-16:15
|
Topic: Successful Financing for Biotech Companies in the Financial Crisis
Alex Chen - Managing Partner, SSG Capital
|
| 16:15-16:25 |
Bill Guo, MD, MBA - Chairman and CEO, Venturepharm Group |
|
16:25-17:25
|
Panel: Public Market Financing - Exit Opportunities for Biotech Companies
The best opportunity for a large payoff for a life science company is to issue shares on a public stock exchange. The opening up of the IPO market in China this year makes this a real possibility. This panel explores the opportunities for life science companies to secure significant growth funding, but changes the way a company must be run.
Moderator: Alex Chen- Managing Partner, SSG Capital
Panelists:
Mark Ma, MBA - Managing Director, CCBI Healthcare Fund
Ying Wang, MBA - Vice President, Northern Light Venture Capital
Wayne Xiong - Partner, WI Harper Group
Shiyuan Zhang- General Manager, Southwest Securities Research and Development Center
Gang Zhao - Managing Director, Director, SBCVC
|
| 17:25-19:00 |
SEED Business Plan Competition Reception |
>> Click here to register
|
